{"id":"CHEMBL105318","canonicalSmiles":"Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O","inchiKey":"UXCAQJAQSWSNPQ-XLPZGREQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALOVUDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alovudine","CL 184,824","CL 184824","CL-184,824","CL-184824","NSC-140025"],"crossReferences":{"PubChem":["144205929","170466324"],"Wikipedia":["Alovudine"],"drugbank":["DB06198"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1084172","canonicalSmiles":"O=C(O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O","inchiKey":"KLOLZALDXGTNQE-JIDHJSLPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VILANTEROL TRIFENATATE","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1198857","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GW-642444M","GW642444M","Vilanterol (as trifenatate)","Vilanterol trifenatate"],"crossReferences":{"DailyMed":["vilanterol%20trifenatate"],"chEBI":["75040"]},"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["EFO_0000464","EFO_0006505","MONDO_0004979","EFO_0000341"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications."}
{"id":"CHEMBL11","canonicalSmiles":"CN(C)CCCN1c2ccccc2CCc2ccccc21","inchiKey":"BCGWQEUPMDMJNV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"IMIPRAMINE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Antideprin","Berkomine","Cristalia","Imipramine","Janimine","Melipramine","NSC-169866","ORG-2463","Pramine","Presamine","Sermonil","Tofranil","Tofranil-PM","Trimipramine maleate impurity, imipramine-"],"crossReferences":{"DailyMed":["imipramine%20hydrochloride","imipramine%20pamoate"],"PubChem":["104171178","11111330","11111331","124880469","144203725","170464777","26751600","50100256","50104254","90341377"],"TG-GATEs":["69"],"Wikipedia":["Imipramine"],"drugbank":["DB00458"],"chEBI":["47499"]},"childChemblIds":["CHEMBL3989845","CHEMBL1692"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002009","HP_0000726","MONDO_0024290","EFO_0004278","MONDO_0007254","EFO_0003948","EFO_0009562","EFO_0008623","MONDO_0002050","EFO_0010282","EFO_0004287","EFO_0009687","EFO_0003761","HP_0003419","EFO_0000612","HP_0100749","EFO_0005230","EFO_0000519"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1171754","canonicalSmiles":"O=C(c1ccc(Oc2ccc(F)cc2)nc1)N1CCCN(C2CCC2)CC1","inchiKey":"IQOWHZHNGJXGHG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-39220675","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj 39220675","Jnj-39220675"],"crossReferences":{"drugbank":["DB12929"]},"linkedTargets":{"rows":["ENSG00000101180"],"count":1},"linkedDiseases":{"rows":["EFO_0005854"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1200531","canonicalSmiles":"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl","inchiKey":"AQORHZJDCHLLJN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ALFENTANIL HYDROCHLORIDE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL634","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alfenta","Alfentanil","Rapifen","Rapifen conc","Rapifen dilute","Rapifen intensive care"],"synonyms":["Alfentanil hydrochloride","Alfentanil hydrochloride cii","Alfentanil hydrochloride monohydrate","R 39,209","R 39209","R-39,209","R-39209"],"crossReferences":{"PubChem":["144206431","85273815"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200776","canonicalSmiles":"C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl","inchiKey":"QANQWUQOEJZMLL-PKLMIRHRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CINACALCET HYDROCHLORIDE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201284","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mimpara","Sensipar"],"synonyms":["AMG-073","AMG-073 HCL","AMG073 HCL","AMG073 HYDROCHLORIDE","Cinacalcet hcl","Cinacalcet hydrochloride"],"crossReferences":{"DailyMed":["cinacalcet%20hydrochloride"],"PubChem":["144206207","170465336"],"chEBI":["48391"]},"linkedTargets":{"rows":["ENSG00000036828"],"count":1},"linkedDiseases":{"rows":["EFO_1001173","EFO_0003884","EFO_0000673","EFO_0000313","EFO_1000456"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 1 investigational indication."}
{"id":"CHEMBL1200866","canonicalSmiles":"FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br","inchiKey":"WTWWXOGTJWMJHI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERFLUBRON","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Imagent"],"synonyms":["N-perfluorooctyl bromide","Perflubron","Perfluorocaprylyl bromide","Perfluoroctyl bromide","Perfluorooctylbromide","Pfob"],"crossReferences":{"PubChem":["144205906","170465144","29217975"],"drugbank":["DB05791"],"chEBI":["38803"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993 and has 1 investigational indication."}
{"id":"CHEMBL1201018","canonicalSmiles":"N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O","inchiKey":"WKJGTOYAEQDNIA-IOOZKYRYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFACLOR","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL680","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bacticlor mr","Ceclor","Ceclor cd","Cefaclor","Distaclor","Distaclor mr","Keftid","Raniclor"],"synonyms":["COMPOUND 99638","COMPOUND-99638","Cefaclor","Cefaclor monohydrate","J01DC04","NSC-757422"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 9 approved and 1 investigational indication."}
{"id":"CHEMBL1201262","canonicalSmiles":"CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1","inchiKey":"OCUJLLGVOUDECM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPIVEFRIN","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["DPE","Dipivalyl epinephrine","Dipivefrin","Dipivefrine"],"crossReferences":{"Wikipedia":["Dipivefrine"],"drugbank":["DB00449"],"chEBI":["4646"]},"childChemblIds":["CHEMBL1200833"],"linkedTargets":{"rows":["ENSG00000184160","ENSG00000274286","ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778","ENSG00000150594"],"count":9},"linkedDiseases":{"rows":["EFO_0000516"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for glaucoma."}
{"id":"CHEMBL1201513","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"HEPARIN CALCIUM","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calciparine","Uniparin ca"],"synonyms":["Ecasolv","Heparin calcium","Heparin calcium salt","Heparinum calcicum"],"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["EFO_0003106","EFO_0003966","EFO_1000965","HP_0002619","HP_0004419","EFO_1000954"],"count":6},"description":"Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 2 investigational indications."}
{"id":"CHEMBL1201828","drugType":"Antibody","blackBoxWarning":true,"name":"ECULIZUMAB","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Soliris"],"synonyms":["5G1.1","ABP-959","Alexion","Eculizumab","Elizaria","H5G1-1","H5G1.1","H5G1.1VHC+H5G1.1VLC","H5G11"],"crossReferences":{"DailyMed":["eculizumab"],"DrugCentral":["4969"],"Wikipedia":["Eculizumab"]},"linkedTargets":{"rows":["ENSG00000106804"],"count":1},"linkedDiseases":{"rows":["Orphanet_2134","EFO_0001365","EFO_1001311","EFO_0000540","MONDO_0004784","EFO_0004599","HP_0001873","EFO_0000565","Orphanet_93571","MONDO_0100096","MONDO_0001549","EFO_0000398","EFO_0003884","EFO_0009473","EFO_0007292","EFO_0004256","EFO_0004826","EFO_0004991","EFO_0000400","Orphanet_447"],"count":20},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1213270","canonicalSmiles":"COC(=O)C1=C(C(=O)OC)[C@@H]2O[C@H]1C(c1ccc(O)cc1)=C2c1ccc(O)cc1","inchiKey":"CRLQCBACIMUGDZ-BGYRXZFFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1213270","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07932"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL122055","canonicalSmiles":"O=C(O)c1ccc(-c2c(F)cccc2F)cc1","inchiKey":"CWWIIKLXUPZDOG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL122055","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06935"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1328","canonicalSmiles":"CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O","inchiKey":"NEYNJQRKHLUJRU-DZUOILHNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTAGASTRIN","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Peptavlon"],"synonyms":["AY-6608","ICI 50,123","ICI-50123","NSC-367746","Pentagastrin"],"crossReferences":{"PubChem":["144207028","170465396"],"Wikipedia":["Pentagastrin"],"drugbank":["DB00183"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974."}
{"id":"CHEMBL146927","canonicalSmiles":"N[C@H]1C[C@@H](C(=O)O)CC1=C(F)F","inchiKey":"CBSRETZPFOBWNG-UCORVYFPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CPP-115","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297273"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL148674","canonicalSmiles":"CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1","inchiKey":"BHLXTPHDSZUFHR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VARESPLADIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-315920","LY315920","Varepladib","Varespladib","Varespladib sodium"],"crossReferences":{"PubChem":["174006184"],"Wikipedia":["Varespladib"],"drugbank":["DB11909"]},"childChemblIds":["CHEMBL2107809"],"linkedTargets":{"rows":["ENSG00000188257"],"count":1},"linkedDiseases":{"rows":["MONDO_0100096","Orphanet_232","EFO_0001645"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL153479","canonicalSmiles":"Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1","inchiKey":"JBDGDEWWOUBZPM-XYPYZODXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMBROXOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ambroxol","Ambroxol hydrochloride","Tabcin"],"crossReferences":{"PubChem":["29215331","50085991"],"Wikipedia":["Ambroxol"],"drugbank":["DB06742"]},"childChemblIds":["CHEMBL1514634"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL1625260","canonicalSmiles":"CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(C)C)c1ccccc1CC2","inchiKey":"KJAMZCVTJDTESW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIRACIZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tiracizine"],"crossReferences":{"PubChem":["144206671"],"drugbank":["DB13635"]},"childChemblIds":["CHEMBL1590144"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1678","canonicalSmiles":"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl","inchiKey":"XWAIAVWHZJNZQQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DONEPEZIL HYDROCHLORIDE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL502","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aricept","Aricept evess","Aricept odt","Donepezil hydrochloride"],"synonyms":["BNAG","Donepezil hcl","Donepezil hydrochloride","E-2020","E2020","NSC-737535","NSC-758882"],"crossReferences":{"DailyMed":["donepezil%20hydrochloride"],"PubChem":["144206087","170464858","26719734","49732006"],"chEBI":["4696"]},"linkedTargets":{"rows":["ENSG00000087085"],"count":1},"linkedDiseases":{"rows":["EFO_0005762","EFO_0004718","HP_0000726","EFO_1001454","EFO_0003758","EFO_0009267","EFO_0006792","Orphanet_778","MONDO_0005277","HP_0100543","MONDO_0002050","EFO_0003884","MONDO_0004975","EFO_0001064","EFO_1000158"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for alzheimer disease and dementia and has 10 investigational indications."}
{"id":"CHEMBL1712170","canonicalSmiles":"CCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314","inchiKey":"OGDVEMNWJVYAJL-LEPYJNQMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHYLMORPHINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3-ethoxymorphine","Codethyline","Ethylmorphine","R05DA01"],"crossReferences":{"PubChem":["144206163","50113064"],"drugbank":["DB01466"],"chEBI":["4902"]},"childChemblIds":["CHEMBL2107695"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1722","canonicalSmiles":"COC(=O)C(c1ccccc1)C1CCCCN1.Cl","inchiKey":"JUMYIBMBTDDLNG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"METHYLPHENIDATE HYDROCHLORIDE","yearOfFirstApproval":1955,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL796","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adhansia xr","Aptensio xr","Concerta","Delmosart","Equasym","Equasym xl","Jornay pm","Matoride xl","Medikinet","Medikinet xl","Metadate cd","Metadate er","Methylin","Methylin er","Methylphenidate hydrochloride","Quillichew er","Quillivant xr","Ritalin","Ritalin la","Ritalin sr","Ritalin-sr","Tranquilyn","Xenidate xl"],"synonyms":["Aptensio","Aptensio xr","Foquest","Metadate","Methylphenidate HCl","Methylphenidate hcl","Methylphenidate hydrochloride","Methylphenidate hydrochloride cii","NSC-169868","Oros mph","Quillichew","Quillivant","SPD-544","SPD544"],"crossReferences":{"DailyMed":["methylphenidate%20hydrochloride"],"PubChem":["144204737","144207507","17389819"],"chEBI":["31836"]},"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["EFO_0003888","Orphanet_209908","EFO_0003840","MONDO_0002050","EFO_0004216","MONDO_0045054","EFO_0003768","EFO_0003929","EFO_0008568","HP_0012378","EFO_0004242","EFO_0000311"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and has 8 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1743048","drugType":"Antibody","blackBoxWarning":true,"name":"OBINUTUZUMAB","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gazyvaro"],"synonyms":["AFUTUZUMAB","Afutuzumab","GA-101","GA101","Gazyva","HUMAB<CD20>","HUMABCD20","Obinutuzumab","R-7159","RG-7159","RO 5072759","RO 5072759 HUMAB<CD20>","RO-5072759","RO-5072759 HUMAB<CD20>","Ro5072759"],"crossReferences":{"DailyMed":["obinutuzumab"],"DrugCentral":["4983"]},"linkedTargets":{"rows":["ENSG00000156738"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","EFO_1001469","EFO_0005952","EFO_1001951","EFO_0000565","EFO_0000309","EFO_1001480","EFO_0000096","EFO_1000956","EFO_0002690","MONDO_0019088","EFO_0003884","EFO_0000183","MONDO_0002083","EFO_0009441","EFO_0000616","MONDO_0013730","EFO_0005761","MONDO_0019465","EFO_0000220","EFO_0000403","EFO_0004236","MONDO_0017596","EFO_0003060","EFO_0000311","EFO_0000304","MONDO_0001023","EFO_0000095","EFO_0000574","EFO_1001051","MONDO_0018906"],"count":31},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 19 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1767408","canonicalSmiles":"O=c1ccn([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1.[Na+].[Na+].[Na+].[Na+]","inchiKey":"OWTGMPPCCUSXIP-FNXFGIETSA-J","drugType":"Small molecule","blackBoxWarning":false,"name":"DIQUAFOSOL TETRASODIUM","maximumClinicalTrialPhase":3,"parentId":"CHEMBL221326","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DE-089","Diquafosol sodium","Diquafosol tetrasodium","Diquafosol tetrasodium salt","INS 365","INS365","KPY-998"],"crossReferences":{"Wikipedia":["Diquafosol"]},"linkedTargets":{"rows":["ENSG00000186912","ENSG00000169860","ENSG00000175591","ENSG00000171631"],"count":4},"linkedDiseases":{"rows":["EFO_1000906"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL1946170","canonicalSmiles":"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1","inchiKey":"FNHKPVJBJVTLMP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"REGORAFENIB","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Stivarga"],"synonyms":["BAY 73-4506","BAY 73-4506 monohydrate","BAY-73-4506","BAY-734506","Regorafenib"],"crossReferences":{"DailyMed":["regorafenib"],"PubChem":["137275982"],"Wikipedia":["Regorafenib"],"drugbank":["DB08896"],"chEBI":["68647"]},"linkedTargets":{"rows":["ENSG00000128052","ENSG00000165731","ENSG00000066468","ENSG00000037280","ENSG00000185386","ENSG00000120156","ENSG00000157404","ENSG00000142627","ENSG00000113721","ENSG00000134853","ENSG00000097007","ENSG00000102755","ENSG00000077782","ENSG00000157764","ENSG00000111816","ENSG00000132155","ENSG00000162733","ENSG00000198400"],"count":18},"linkedDiseases":{"rows":["MONDO_0003060","EFO_0000637","EFO_0000365","EFO_0001075","MONDO_0015686","EFO_0000756","EFO_0000681","EFO_1000657","MONDO_0021063","EFO_0000231","EFO_1001951","EFO_0009606","MONDO_0001056","EFO_1001480","MONDO_0002158","EFO_1000218","EFO_1000044","EFO_0003968","EFO_0000389","EFO_0000182","EFO_0005540","MONDO_0044919","EFO_1001949","EFO_0000616","EFO_0002618","EFO_0003893","MONDO_0002108","MONDO_0008170","Orphanet_44890","EFO_0005842","MONDO_0007576","EFO_0000313","EFO_0000222","EFO_1001968","EFO_0005221","EFO_0000311","EFO_0004142","EFO_0000702","EFO_0000691","EFO_0000519","EFO_0000569"],"count":41},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 30 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1951714","canonicalSmiles":"CCCCCCCCCCCCCCCCCCCCCCCCCCCCO","inchiKey":"CNNRPFQICPFDPO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTACOSANOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cluytyl alcohol","N-octacosanol","NSC-10770","Octacosan-1-ol","Octacosanol","Octanosol"],"crossReferences":{"drugbank":["DB11220"],"chEBI":["28243"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1956820","canonicalSmiles":"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(P(=O)(O)Cc6c(F)cccc6F)C[C@H]5CCCCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(C)C)n3)nc2c1Cl","inchiKey":"RFGUWOCFYCYEDM-ZOMNBDOOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GS-9256","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-9256","Gs-9256"],"crossReferences":{"drugbank":["DB12876"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1969664","canonicalSmiles":"N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1","inchiKey":"BLTVBQXJFVRPFK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-1080","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZ-11548415","AZD-1080","Azd-1080"],"crossReferences":{"PubChem":["103905163"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL198362","canonicalSmiles":"O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1","inchiKey":"KGFYHTZWPPHNLQ-AWEZNQCLSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"RIVAROXABAN","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xarelto"],"synonyms":["BAY 59-7939","BAY-59-7939","JNJ-39039039","JNJ39039039","Rivaroxaban"],"crossReferences":{"DailyMed":["rivaroxaban"],"Wikipedia":["Rivaroxaban"],"drugbank":["DB06228"],"chEBI":["68579"]},"linkedTargets":{"rows":["ENSG00000126218"],"count":1},"linkedDiseases":{"rows":["EFO_0003777","EFO_0000275","Orphanet_232","EFO_0009531","EFO_0000266","EFO_0003914","HP_0000083","HP_0030242","EFO_0003144","EFO_0000712","EFO_0003884","EFO_0003837","EFO_0004616","HP_0004419","EFO_1001161","EFO_0000400","HP_0004936","EFO_0002689","EFO_0002628","EFO_0000616","EFO_0000694","HP_0002140","EFO_0001074","EFO_0001645","EFO_0004286","EFO_0000556","HP_0001873","EFO_0000311","HP_0001907","MP_0001914","EFO_0001422","MONDO_0100096","EFO_0010680","MONDO_0000831","EFO_0003827","EFO_0003907","EFO_0001378","EFO_0000612","EFO_0009314","MONDO_0005148","EFO_0005672","EFO_0004265"],"count":42},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 6 approved and 27 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2016681","canonicalSmiles":"CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2ccc(C(F)(F)F)cn2)CC1","inchiKey":"WGEWUYACXPEFPO-AULYBMBSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VELNEPERIT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["S-2367","Velneperit"],"crossReferences":{"drugbank":["DB12889"]},"linkedTargets":{"rows":["ENSG00000164129"],"count":1},"linkedDiseases":{"rows":["EFO_0001073"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2040681","canonicalSmiles":"CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1.CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@H]3[C@@H]4C[C@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@H]4C(C)=C[C@H]3[C@@H]2CC(=O)O1","inchiKey":"JFLRKDZMHNBDQS-SGSTVUCESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPINOSAD","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Natroba"],"synonyms":[],"crossReferences":{"DrugCentral":["4623"],"drugbank":["DB08823"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL204086","canonicalSmiles":"N[C@@H](Cc1ccccc1)[C@H](O)CNS(=O)(=O)c1ccc2ccccc2c1","inchiKey":"QSSWSEQPKCCATQ-VQTJNVASSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL204086","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07522"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2087003","canonicalSmiles":"NC(=O)OC[C@@H](O)c1ccccc1Cl","inchiKey":"OLBWFRRUHYQABZ-MRVPVSSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARISBAMATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carisbamate","JNJ-10234094","RWJ-333369","RWJ-333369-000","YKP-509"],"crossReferences":{"drugbank":["DB12338"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL2105097","canonicalSmiles":"COc1ccccc1OC(=O)c1ccccc1OC(C)=O","inchiKey":"HSJFYRYGGKLQBT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUACETISAL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aspirin guaiacol ester","Guacetisal","Prontomucil"],"crossReferences":{"drugbank":["DB13538"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2107431","canonicalSmiles":"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C","inchiKey":"YNVGQYHLRCDXFQ-XGXHKTLJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LYNESTRENOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lynestrenol","Lynoestrenol","NSC-37725"],"crossReferences":{"drugbank":["DB12474"],"chEBI":["31790"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108027","drugType":"Protein","blackBoxWarning":true,"name":"DULAGLUTIDE","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Trulicity"],"synonyms":["Dulaglutide","LY-2189265","LY2189265"],"crossReferences":{"DailyMed":["dulaglutide"],"DrugCentral":["4885"]},"linkedTargets":{"rows":["ENSG00000112164"],"count":1},"linkedDiseases":{"rows":["EFO_0004319","MONDO_0005147","HP_0001959","EFO_0003884","HP_0003074","MONDO_0005148","EFO_0000400","EFO_0000660"],"count":8},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108302","drugType":"Protein","blackBoxWarning":false,"name":"SPRIFERMIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AS-902330","AS902330","Sprifermin"],"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109426","drugType":"Antibody","blackBoxWarning":false,"name":"BIW-8962","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIW-8962","Biw-8962"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109664","drugType":"Antibody","blackBoxWarning":false,"name":"ELDELUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-936557","Eldelumab","MDX-1100"],"linkedTargets":{"rows":["ENSG00000169245"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0000685","EFO_0000384"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2110574","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM CHROMATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"chEBI":["78671"]},"childChemblIds":["CHEMBL2096634"],"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2219413","canonicalSmiles":"N=C(N)NCCCCC(=O)Nc1cc(C(F)(F)F)cc(NC(=O)c2cc(C(=O)Nc3cc(C(F)(F)F)cc(NC(=O)CCCCNC(=N)N)c3O[C@@H]3CCNC3)ncn2)c1O[C@@H]1CCNC1","inchiKey":"QPDYBCZNGUJZDK-DNQXCXABSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRILACIDIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Brilacidin","PMX-30063 FREE BASE","PMX30063","PMX30063 FREE BASE"],"crossReferences":{"drugbank":["DB12997"]},"childChemblIds":["CHEMBL2219420","CHEMBL4583215"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL222863","canonicalSmiles":"C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O","inchiKey":"LPMXVESGRSUGHW-HBYQJFLCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OUABAIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-25485","Ouabain"],"crossReferences":{"PubChem":["11533037","124883187","124883189","144203575","144205610","144211864","170465763","26753626","26753627","50106811","50106812","85231346","90340653","92092794"],"drugbank":["DB01092"],"chEBI":["472805"]},"childChemblIds":["CHEMBL1889436","CHEMBL1357246"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."}
{"id":"CHEMBL226345","canonicalSmiles":"Nc1ncnc2[nH]cnc12","inchiKey":"GFFGJBXGBJISGV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADENINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adenine","NSC-14666"],"crossReferences":{"PubChem":["144204901","144212425","170465950","26748402","47193680","540768"],"Wikipedia":["Adenine"],"drugbank":["DB00173"],"chEBI":["16708"]},"childChemblIds":["CHEMBL539503","CHEMBL1597282"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL230172","canonicalSmiles":"CCc1ccc(NS(=O)(=O)c2ccc(F)cc2)c(C(=O)O)c1C","inchiKey":"MGUQWAOYPINSIT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL230172","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07746"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL232942","canonicalSmiles":"N#CC1=C(c2cc(Cl)cc(Cl)c2)C(=O)N2CCC[C@]12Cc1ccc(C#N)cc1","inchiKey":"TZCXQSNBTXDAJG-QFIPXVFZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL232942","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06972"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2364609","canonicalSmiles":"CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl","inchiKey":"VCMGMSHEPQENPE-ZOWNYOTGSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ESKETAMINE HYDROCHLORIDE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL395091","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Spravato"],"synonyms":["AM-101","Esketamine hydrochloride","Ketamine hydrochloride, (s)-","Ketamine hydrochloride, s-","Ketanest s"],"crossReferences":{"DailyMed":["esketamine%20hydrochloride"],"chEBI":["60800"]},"linkedTargets":{"rows":["ENSG00000183454","ENSG00000273079","ENSG00000116032","ENSG00000161509","ENSG00000105464","ENSG00000176884","ENSG00000198785"],"count":7},"linkedDiseases":{"rows":["EFO_0000546","HP_0000360","MONDO_0001208","MONDO_0002009","EFO_0003761","EFO_0003843"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for unipolar depression and major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2364611","canonicalSmiles":"Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1","inchiKey":"IVRXNBXKWIJUQB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GALUNISERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Galunisertib","LY-2157299","LY2157299","Ly-2157299"],"crossReferences":{"drugbank":["DB11911"]},"linkedTargets":{"rows":["ENSG00000106799"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_1000412","EFO_0002618","EFO_1000657","EFO_0004252","EFO_0000305","MONDO_0008315","EFO_0009708","EFO_1001480","EFO_0003860","EFO_0000182","EFO_0000326","EFO_0000519"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications."}
{"id":"CHEMBL2397415","canonicalSmiles":"Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12","inchiKey":"JJVAPHYEOZSKJZ-JGCGQSQUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZAVEGEPANT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BHV-3500","BMS-742413","BMS-742413-01","Vazegepant","Zavegepant"],"childChemblIds":["CHEMBL4650220"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL245079","canonicalSmiles":"CC1=C[C@H]2Cc3[nH]c(=O)ccc3[C@]3(C1)NCCC[C@H]23","inchiKey":"YYWGABLTRMRUIT-HWWQOWPSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HUPERZINE B","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03348"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL249120","canonicalSmiles":"Cc1ccc(C)c(N)c1","inchiKey":"VOWZNBNDMFLQGM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2,5-XYLIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2,5-Xylidine"],"crossReferences":{"PubChem":["144208223","17389378","81066855"],"Wikipedia":["2,5-Xylidine"],"drugbank":["DB02163"],"chEBI":["518305"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL250409","canonicalSmiles":"CC(C)(C)NS(=O)(=O)c1ccc(-c2cnc3cccc(Nc4ccccn4)c3c2)cc1","inchiKey":"GJTCKUKIFXWJKG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL250409","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06933"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL257158","canonicalSmiles":"CC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1","inchiKey":"DRHXTSWSUAJOJZ-FMDGEEDCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"N-Acetylglucosamine Thiazoline","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["N-Acetylglucosamine Thiazoline"],"crossReferences":{"drugbank":["DB03747"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL279107","canonicalSmiles":"O=P(O)(O)O[C@H]1[C@H](O)[C@@H](OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"MMWCIQZXVOZEGG-XJTPDSDZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INS(1,4,5)P3","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1,4,5-InsP3","Ionositol 1,4,5-Triphosphate"],"crossReferences":{"drugbank":["DB03401"],"chEBI":["16595"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL286398","canonicalSmiles":"CC(O)CO","inchiKey":"DNIAPMSPPWPWGF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPYLENE GLYCOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Sentry propylene glycol","Sirlene"],"synonyms":["E-1520","E1520","E490","FEMA NO. 2940","Ins no.1520","Ins-1520","Isopropylene glycol","Kilfrost abc-s","Kollisolv pg","Methyl glycol","NSC-69860","Propylene glycol","Propylene glycol (solvent)","Propylene glycol cefatrizine","Propylene glycol dl-form","Propyleneglycolum"],"crossReferences":{"PubChem":["144209010","144210326","144211758","17389749","49816670"],"Wikipedia":["Propylene_glycol"],"drugbank":["DB01839"],"chEBI":["16997"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL296468","canonicalSmiles":"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1","inchiKey":"OUSFTKFNBAZUKL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-387032","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-387032","Bms-387032","Bms387032","SNS-032","Sns 032"],"crossReferences":{"PubChem":["103905658","137276011","50100091"],"drugbank":["DB05969"]},"linkedTargets":{"rows":["ENSG00000123374","ENSG00000134058","ENSG00000136807"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000095","EFO_0001378","EFO_1001469","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL299175","canonicalSmiles":"COc1cc(CC2NCCc3cc(O)c(O)cc32)cc(OC)c1OC","inchiKey":"RGVPOXRFEPSFGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRETOQUINOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-)-tretoquinol","AQ-110","Dl-trimetoquinol","Inolin","NSC-288748","RO-07-5965","Racemic-trimetoquinol","S-(-)-tretoquinol","Tretoquinol","Tretoquinol hydrochloride","Tretoquinol, (-)-","Trimethoquinol","Trimetoquinol hydrochloride"],"childChemblIds":["CHEMBL542101"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3039542","drugType":"Protein","blackBoxWarning":false,"name":"CIMAGLERMIN ALFA","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cimaglermin alfa","GGF-2","GGF2","Glial growth factor 2","Neuroglia growth factor 2","RHGGF-2","rhGGF2"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3137685","drugType":"Small molecule","blackBoxWarning":false,"name":"NEDAPLATIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aqupla","Cis-diammine-glycolatoplatinum","NSC-375101D","Nedaplatin"],"crossReferences":{"chEBI":["31898"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL313972","canonicalSmiles":"C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1","inchiKey":"HCZKYJDFEPMADG-TXEJJXNPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MASOPROCOL","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Actinex"],"synonyms":["CHX-100","INSM-18","MESO-NDGA","Masoprocol","Meso-nordihydroguaiaretic acid","NSC-4291","NSC-682984","Nordihydroguaiaretic acid"],"crossReferences":{"PubChem":["11111540","11111541","124891671","144203761","50100292","50106727","50106728","90341429"],"Wikipedia":["Masoprocol"],"drugbank":["DB00179"],"chEBI":["73468"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 1 investigational indication."}
{"id":"CHEMBL3186027","canonicalSmiles":"CC(CC=O)CCCC(C)(C)O","inchiKey":"WPFVBOQKRVRMJB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3186027","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144206234","144211491","225144317"],"drugbank":["DB14187"],"chEBI":["53459"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL324547","canonicalSmiles":"CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1","inchiKey":"YDZYKNJZCVIKPP-VWLOTQADSA-N","drugType":"Protein","blackBoxWarning":false,"name":"NETAZEPIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Netazepide","Sograzepide","YF-476","Yf476"],"crossReferences":{"drugbank":["DB12355"]},"linkedTargets":{"rows":["ENSG00000110148"],"count":1},"linkedDiseases":{"rows":["EFO_0000280","EFO_0004243","EFO_0007549","EFO_1001095","EFO_0008533"],"count":5},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL3287735","canonicalSmiles":"CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21","inchiKey":"FKSFKBQGSFSOSM-QFIPXVFZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK2816126","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gsk2816126"],"linkedTargets":{"rows":["ENSG00000106462"],"count":1},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3301594","canonicalSmiles":"COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O","inchiKey":"SWMDAPWAQQTBOG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSTEMSAVIR","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BMS-663068","Bms-663068 free acid","Fostemsavir"],"crossReferences":{"DailyMed":["fostemsavir%20tromethamine"],"drugbank":["DB11796"]},"childChemblIds":["CHEMBL3301598"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved indications."}
{"id":"CHEMBL346631","canonicalSmiles":"CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCOC(=O)CN(C)C)Cc1ccccc1-4)C(=O)NC3","inchiKey":"UHEBDUAFKQHUBV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEP-7055","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CEP-7055","Cep-7055"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL351132","canonicalSmiles":"Cc1cc2nc[nH]c2cc1C","inchiKey":"LJUQGASMPRMWIW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIMEDAZOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5,6-Dimethylbenzimidazole","Dimedazol"],"crossReferences":{"drugbank":["DB02591"],"chEBI":["15890"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544966","canonicalSmiles":"O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1","inchiKey":"QDITZBLZQQZVEE-YBEGLDIGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-1059615","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-615","GSK1059615","GSK615","Gsk-1059615"],"crossReferences":{"drugbank":["DB11962"]},"linkedTargets":{"rows":["ENSG00000145675","ENSG00000171608","ENSG00000105647","ENSG00000141506","ENSG00000051382","ENSG00000121879","ENSG00000105851","ENSG00000117461"],"count":8},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545010","canonicalSmiles":"CCN1CCC(c2cccc(S(C)(=O)=O)c2F)CC1","inchiKey":"UKUPJASJNQDHPH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORDOPIDINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACR-325","ACR325","Acr325","Ordopidine"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["MONDO_0005180"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545159","drugType":"Small molecule","blackBoxWarning":false,"name":"R-333","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R-333"],"linkedTargets":{"rows":["ENSG00000165025","ENSG00000105639"],"count":2},"linkedDiseases":{"rows":["EFO_0002690"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545192","drugType":"Antibody","blackBoxWarning":false,"name":"MIRVETUXIMAB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["M-9346A","M9346A","Mirvetuximab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545369","canonicalSmiles":"NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1","inchiKey":"FBKMWOJEPMPVTQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPACADOSTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epacadostat","INCB-024360","INCB024360"],"crossReferences":{"drugbank":["DB11717"]},"linkedTargets":{"rows":["ENSG00000131203"],"count":1},"linkedDiseases":{"rows":["EFO_0001075","MONDO_0015686","EFO_0000756","EFO_0000681","EFO_1000657","MONDO_0002087","MONDO_0001187","MONDO_0000548","EFO_1001480","MONDO_0002158","EFO_1000044","EFO_0000389","MONDO_0008903","EFO_1000251","EFO_0000196","EFO_0008528","EFO_0000198","EFO_0000616","Orphanet_145","EFO_0006859","EFO_1000616","MONDO_0008170","Orphanet_44890","EFO_1001512","EFO_0000222","MONDO_0044881","EFO_0003060","EFO_0003863","EFO_1000576","MONDO_0000544","EFO_0002517","MONDO_0011962","EFO_0000702","EFO_0000574","MONDO_0024880","EFO_0000691","EFO_0000519","EFO_0000181"],"count":38},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 31 investigational indications."}
{"id":"CHEMBL3545391","canonicalSmiles":"CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C","inchiKey":"DFELGYQKEOCHOA-RBXNTRDFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORG-34517","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ORG 34517","ORG-34517","ORG34517","Org-34517","PT-150","PT150","Pt150","SCH 900636","SCH-900636"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["MONDO_0002050","MONDO_0002009","MONDO_0007079"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3682589","canonicalSmiles":"O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc3ccccc3c2C2CC2)cc1","inchiKey":"CWEFDWIKLABKBX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELISMETREP","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Elismetrep","MT-8554","Mt-8554"],"crossReferences":{"drugbank":["DB15287"]},"linkedTargets":{"rows":["ENSG00000144481"],"count":1},"linkedDiseases":{"rows":["EFO_1000783","HP_0031217"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3707226","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"DEFIBROTIDE SODIUM","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Defitelio"],"synonyms":["Defibrotide sodium","JZP-381"],"crossReferences":{"DailyMed":["defibrotide%20sodium"]},"linkedTargets":{"rows":["ENSG00000122194"],"count":1},"linkedDiseases":{"rows":["MONDO_0019514"],"count":1},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for hepatic veno-occlusive disease."}
{"id":"CHEMBL371668","canonicalSmiles":"O=C(COP(=O)(O)O)NO","inchiKey":"BAXHHWZKQZIJID-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSPHOGLYCOLOHYDROXAMATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosphoglycolohydroxamate","Phosphoglycolohydroxamic Acid","Phosphoric Acid Monohydroxycarbamoylmethyl Ester"],"crossReferences":{"drugbank":["DB03026"],"chEBI":["28475"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL374478","canonicalSmiles":"CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C","inchiKey":"JQXXHWHPUNPDRT-WLSIYKJHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIFAMPIN","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eremfat","Rifadin","Rifampicin","Rifampin","Rimactane"],"synonyms":["Abrifam","BA 411661E","BA-41166E","L-5103","L-5103 LEPETIT","L-5103-LEPETIT","NIH-10782","NSC-113926","Rifadine","Rifaldazine","Rifaldin","Rifampicin","Rifampicinum","Rifampin","Rifamycin amp","Rifapiam","Rifaprodin","Rifoldin","Rimactan"],"crossReferences":{"DailyMed":["rifampin"],"PubChem":["144204882","144208583","144210868","170464760"],"TG-GATEs":["8"],"drugbank":["DB01045"],"chEBI":["28077"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for tuberculosis and pulmonary tuberculosis and has 46 investigational indications."}
{"id":"CHEMBL380589","canonicalSmiles":"CCCCNc1cc(C)nc2nc(Nc3cc(Cl)ccc3C)nn12","inchiKey":"ZTYBIJUAAWLJNU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL380589","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07128"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL383634","canonicalSmiles":"COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C","inchiKey":"LLJFMFZYVVLQKT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLIQUIDONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Glurenorm"],"synonyms":["ARDF 26","ARDF-26","Gliquidone"],"crossReferences":{"PubChem":["11112731","144204180","170465581","50085433"],"Wikipedia":["Gliquidone"],"drugbank":["DB01251"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for diabetes mellitus."}
{"id":"CHEMBL397976","canonicalSmiles":"O=C1CC[C@@H](C(=O)O)N1","inchiKey":"ODHCTXKNWHHXJC-VKHMYHEASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIDOLIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-l-oxoproline","5-oxoproline","Ajidew a-100","Glutimic acid","L-pca","L-pyroglutamic acid","L-pyrrolidone carboxylic acid","NSC-143034","NSC-760414","Pidolic acid","Pidolidone","Pyroglu","Pyroglutamate","Pyroglutamic acid","Pyroglutamic acid, l-"],"crossReferences":{"PubChem":["144205489","170466347","29216300","57260135"],"drugbank":["DB03088"],"chEBI":["18183"]},"childChemblIds":["CHEMBL3707303"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3986824","canonicalSmiles":"Nc1cncc(-c2cn3ccnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1","inchiKey":"XCIGZBVOUQVIPI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LANRAPLENIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-SYK","Lanraplenib"],"crossReferences":{"drugbank":["DB14770"]},"childChemblIds":["CHEMBL4298174"],"linkedTargets":{"rows":["ENSG00000165025"],"count":1},"linkedDiseases":{"rows":["EFO_0003834","EFO_0002690","EFO_0000222","EFO_0000540","EFO_0000699"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3990033","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"INCLISIRAN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ALN-60212","ALN-PCSSC","ALN-PSCsc","Inclisiran","Leqvio"],"linkedTargets":{"rows":["ENSG00000169174"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","HP_0003124","MONDO_0021187","Orphanet_391665","EFO_0000319","EFO_0004911","EFO_0005672"],"count":7},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 6 investigational indications."}
{"id":"CHEMBL4079239","canonicalSmiles":"C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl","inchiKey":"CWFVVQFVGMFTBD-SECBINFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-54175446","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-54175446"],"crossReferences":{"drugbank":["DB15358"]},"linkedTargets":{"rows":["ENSG00000089041"],"count":1},"linkedDiseases":{"rows":["MONDO_0002009"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL410448","canonicalSmiles":"COCCNc1cc(-n2c3c(c4ccccc42)C(=O)CCC3)ccc1C(N)=O","inchiKey":"XQKFKSJUBJPOLY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL410448","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08557"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4210847","canonicalSmiles":"CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21","inchiKey":"ZUHZNKJIJDAJFD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-00489791","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-489,791","Pf-00489791","UK-489,791"],"crossReferences":{"drugbank":["DB11736"]},"linkedTargets":{"rows":["ENSG00000138735"],"count":1},"linkedDiseases":{"rows":["EFO_0001361","EFO_0000401","EFO_1001145","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL42632","canonicalSmiles":"C[C@H](Nc1ncnc2cc(F)c(F)cc12)C(c1ccccc1)c1ccccc1","inchiKey":"WVGZKPGUHOZIJQ-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL42632","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03678"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4279455","canonicalSmiles":"CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C","inchiKey":"DXOJIXGRFSHVKA-BZVZGCBYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAROTAXEL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Larotaxel","XRP-9881","XRP9881","Xrp9881"],"crossReferences":{"drugbank":["DB12984"]},"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000101162","ENSG00000196230","ENSG00000137285","ENSG00000176014"],"count":9},"linkedDiseases":{"rows":["EFO_0000294","EFO_0003869","EFO_0003860","MONDO_0007254"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297184","canonicalSmiles":"Cc1ccc(-c2nc(N)nc3c2nnn3Cc2cccc(CO[C@H]3CCOC3)n2)o1","inchiKey":"KURQKNMKCGYWRJ-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CIFORADENANT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CPI-444","Ciforadenant","V-81444","V81444"],"linkedTargets":{"rows":["ENSG00000128271"],"count":1},"linkedDiseases":{"rows":["EFO_0003888","MONDO_0005180","EFO_0001378","EFO_0003060"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297228","drugType":"Unknown","blackBoxWarning":false,"name":"BRIVOLIGIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AYX-1","AYX1","Brivoligide"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297307","canonicalSmiles":"N=C1N(O)[C@@H](COC(N)=O)[C@@H]2N=C(N)N[C@]23N1CCC3(O)O","inchiKey":"PPEKGEBBBBNZKS-HGRQIUPRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEOSAXITOXIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Neosaxitoxin","Neostx"],"crossReferences":{"drugbank":["DB12989"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297345","canonicalSmiles":"CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1.Cl","inchiKey":"XROFSGVHHSJMMG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADL-5747","maximumClinicalTrialPhase":2,"parentId":"CHEMBL561339","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADL5747","Adl-5747","Adl5747"],"linkedTargets":{"rows":["ENSG00000116329"],"count":1},"linkedDiseases":{"rows":["MONDO_0041052","EFO_0004616"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297603","canonicalSmiles":"[2H]C([2H])([2H])C(c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)(C([2H])([2H])[2H])C([2H])([2H])[2H]","inchiKey":"PURKAOJPTOLRMP-ASMGOKTBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEUTIVACAFTOR","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2010601","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CTP-656","Ctp-656","D9-ivacaftor","Deutivacaftor","Ivacaftor d9","VX-561","Vx-561"],"crossReferences":{"drugbank":["DB15141"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297750","drugType":"Antibody","blackBoxWarning":false,"name":"FARICIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Faricimab","RG7716","RG77161","RO-6867461","RO6867461","Rg-7716","Ro6867461","Y8ha1i28d3"],"linkedTargets":{"rows":["ENSG00000091879","ENSG00000112715"],"count":2},"linkedDiseases":{"rows":["EFO_0009606","EFO_0004683","EFO_0001365","EFO_0009321"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297794","drugType":"Antibody","blackBoxWarning":false,"name":"NEMOLIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CIM-331","CIM331","Nemolizumab"],"linkedTargets":{"rows":["ENSG00000164509"],"count":1},"linkedDiseases":{"rows":["MONDO_0026045","EFO_0000274","EFO_0000717"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297935","drugType":"Unknown","blackBoxWarning":false,"name":"RG-7841","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-ly6e-vcmmae","DLYE-5953A","DLYE5953A","Dlye5953a","RG-7841","RG7841","Rg-7841"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000160932","ENSG00000258947","ENSG00000101162","ENSG00000196230","ENSG00000137285","ENSG00000176014"],"count":10},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298021","drugType":"Antibody","blackBoxWarning":false,"name":"ZAGOTENEMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-3303560","LY3303560","Ly-3303560","Ly3303560","Zagotenemab"],"linkedTargets":{"rows":["ENSG00000186868"],"count":1},"linkedDiseases":{"rows":["MONDO_0004975"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298034","drugType":"Unknown","blackBoxWarning":false,"name":"MEDI-8852","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-8852","MEDI8852","Medi 8852","Medi-8852","Medi8852","Pan-influenza a mab medi8852"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298210","drugType":"Antibody","blackBoxWarning":false,"name":"ISCALIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CFZ-533","CFZ533","Iscalimab","NVP-CFZ533"],"linkedTargets":{"rows":["ENSG00000101017"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_0005761","EFO_1000710","EFO_0002690","MONDO_0005147","EFO_0004991","EFO_0004599","EFO_0000699","EFO_0004237"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL4300465","canonicalSmiles":"[Ra]","inchiKey":"HCWPIIXVSYCSAN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RADIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297420"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4303404","canonicalSmiles":"Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=N[C@H]2CC(N)=O","inchiKey":"GCWIQUVXWZWCLE-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CPI-0610","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CPI-0610","Cpi 0610","Cpi-0610","Pelabresib monohydrate"],"linkedTargets":{"rows":["ENSG00000169925","ENSG00000204256","ENSG00000137948","ENSG00000141867"],"count":4},"linkedDiseases":{"rows":["MONDO_0044903","EFO_0000574","EFO_0001378","EFO_0002431"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL45816","canonicalSmiles":"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C","inchiKey":"HBNPJJILLOYFJU-VMPREFPWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIBEFRADIL","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," European Union"," Germany"," Ireland"," Malasia"],"classes":["Cardiotoxicity"],"year":1998},"tradeNames":["Posicor 100","Posicor 50"],"synonyms":["Mibefradil","Posicor"],"crossReferences":{"PubChem":["11111472","26755047","50110875","90340964"],"Wikipedia":["Mibefradil"],"drugbank":["DB01388"],"chEBI":["6920"]},"childChemblIds":["CHEMBL1256688","CHEMBL1534525","CHEMBL1421212"],"linkedTargets":{"rows":["ENSG00000100346","ENSG00000006283","ENSG00000196557"],"count":3},"linkedDiseases":{"rows":["EFO_0000319","EFO_0000519","EFO_1000158"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and has 2 investigational indications. It was withdrawn in United States,  European Union,  Germany,  Ireland and  Malasia initially in 1998 due to Cardiotoxicity."}
{"id":"CHEMBL4597200","canonicalSmiles":"Cl[TeH]1(Cl)(Cl)OCCO1","inchiKey":"NTCZXUFXVRQSMX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMMONIUM TRICHLOROTELLURATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4584965"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4650490","drugType":"Antibody","blackBoxWarning":false,"name":"TOZORAKIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-3506","MEDI3506","Medi3506","Tozorakimab"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4802177","drugType":"Unknown","blackBoxWarning":false,"name":"ORIC-101","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ORIC-101","Oric-101"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL482950","canonicalSmiles":"CC[C@@H](C)Nc1nc(C)nc2c(-c3ccc(OC)nc3C)c(C)nn12","inchiKey":"LBWQSAZEYIZZCE-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PEXACERFONT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-562086","Bms562086","CRF1 ANTAGONIST","Dpc-a69448","Pexacerfont"],"crossReferences":{"drugbank":["DB12572"]},"linkedTargets":{"rows":["ENSG00000120088"],"count":1},"linkedDiseases":{"rows":["EFO_1001892","MONDO_0002009","EFO_0000555"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL483321","canonicalSmiles":"COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1","inchiKey":"LLVZBTWPGQVVLW-SNAWJCMRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CP-724714","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CP-724,714","CP-724714","Cp-724714"],"crossReferences":{"PubChem":["50100096"],"drugbank":["DB12302"]},"linkedTargets":{"rows":["ENSG00000141736"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","MONDO_0007254","EFO_0009708"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL483348","canonicalSmiles":"Cc1nc2c(c(=O)[nH]1)CSCC2","inchiKey":"HRYKZAKEAVZGJD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL483348","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07677"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL485323","canonicalSmiles":"CNC(=O)CN1CCC(Nc2nccc(-c3cnc4ccccn34)n2)CC1","inchiKey":"AJLILYAPRHIFAS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL485323","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08026"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL517427","canonicalSmiles":"COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1","inchiKey":"FAIIFDPAEUKBEP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NILVADIPINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CL 287,389","CL-287,389","CL-287389","Dl-nilvadipine","Escor","FK 235","FK-235","FR-34235","Nilvadipine","Nivadil","Nivadip","Nivadipine","SK&F 102,362","SKF-102362"],"crossReferences":{"PubChem":["144205992","50112689"],"Wikipedia":["Nilvadipine"],"drugbank":["DB06712"]},"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000151067","ENSG00000102001"],"count":4},"linkedDiseases":{"rows":["MONDO_0004975","EFO_0000319"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL535650","canonicalSmiles":"Cl.OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1","inchiKey":"WESWYMRNZNDGBX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MEFLOQUINE HYDROCHLORIDE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL416956","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fansimef","Lariam","Mefloquine hydrochloride"],"synonyms":["Loriam","Mefloquine hcl","Mefloquine hydrochloride","Mefloquini hydrochloridum","NSC-157387","RO 21-5998/001","RO-21-5998","RO-215998001","WR-142490"],"crossReferences":{"DailyMed":["mefloquine%20hydrochloride"],"PubChem":["56463353"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL595573","canonicalSmiles":"O=C1O[C@]2(CC[C@H](C(=O)Nc3ccn(-c4ccccc4F)n3)CC2)c2cnccc21","inchiKey":"RMYZIRFUCOMQRH-CAJLXGCNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-0557","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-0557","MK0557","Mk-0557","Mk0557"],"crossReferences":{"drugbank":["DB12168"]},"linkedTargets":{"rows":["ENSG00000164129"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0001073"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL65273","canonicalSmiles":"N[C@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)NCCNc1ccncc1","inchiKey":"GEIDRYBJURDUSW-MOPGFXCFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL65273","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08422"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL67166","canonicalSmiles":"CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO","inchiKey":"WWUZIQQURGPMPG-KRWOKUGFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPHINGOSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D-Sphingosine"],"crossReferences":{"PubChem":["124384872","26751809","26751810","26751811","50104502","50104503","50104504","56320653"],"Wikipedia":["Sphingosine"],"drugbank":["DB03203"],"chEBI":["16393"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL82321","canonicalSmiles":"Nc1cccc2cc3ccccc3cc12","inchiKey":"YUENFNPLGJCNRB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-Aminoanthracene","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Aminoanthracene","Anthracen-1-Ylamine"],"crossReferences":{"Wikipedia":["Anthramine"],"drugbank":["DB01976"],"chEBI":["40678"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL960","canonicalSmiles":"Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1","inchiKey":"VHOGYURTWQBHIL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LEFLUNOMIDE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Arava","Leflunomide"],"synonyms":["HWA-486","L04AA13","Leflunomide","Leflunomide medac","Leflunomide ratiopharm","Leflunomide teva","Leflunomide winthrop","NSC-677411","NSC-759864","Repso","SU-101","SU101","SULOL"],"crossReferences":{"DailyMed":["leflunomide"],"PubChem":["11111382","11111383","124880563","124880568","144203733","144212190","170464823","174006674","26746985","26746986","26746987","50100264","50104054","50104055","50104056","56422128","85231115","855764","90341277"],"Wikipedia":["Leflunomide"],"drugbank":["DB01097"],"chEBI":["6402"]},"linkedTargets":{"rows":["ENSG00000102967"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003073","EFO_0000685","EFO_0005761","MONDO_0013730","EFO_1000965","EFO_0000756","MONDO_0007254","EFO_0003778","EFO_0000540","MONDO_0008315","EFO_0002609","EFO_0007187","EFO_1001231","EFO_0008518","MONDO_0100096","EFO_0002690","MONDO_0005301","Orphanet_238510","EFO_0000764","EFO_0001378","EFO_0004991","EFO_0000699","EFO_1000158"],"count":24},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 18 investigational indications. This drug has a black box warning from the FDA."}
